People | July 10, 2024
AbbVie appoints Roopal Thakkar as EVP, Research & Development and Chief Scientific Officer
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Open a printable version of this pageEmail the URL of this page to a friend
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
Subscribe To Our Newsletter & Stay Updated
